Oliver Eckelmann, Ph.D.

Oliver Eckelmann, Ph.D. has a diverse and extensive work experience in various industries. Oliver is currently the Group CEO and Co-Founder of discoveric bio group, where they lead the development and manufacturing of antibodies for neurological, infectious, auto-immune, and oncology therapies. Oliver also co-founded and serves as the Director of Board of Directors of Medical Templates AG, a company that develops and commercializes The Cube Navigation System for image-guided interventions.

In addition, Dr. Eckelmann is the Director of Board of Directors and Co-Founder of discovermarket, a company focused on disrupting how insurers reach their market. Oliver previously held the positions of COO and CFO at NovImmune, where they led the acquisition and restructure of the company, and Group COO and CFO at LamKap Bio Group, where they created and launched a group of biotechs focused on antibody-based disease treatment.

Prior to these roles, Dr. Eckelmann worked at Entsia, a global solution-focused digital player, and discoveric ag, where they transformed the organization into a large private equity family office and led portfolio expansion. Oliver also had a successful career at Roche, where they held the positions of CFO, Deputy CEO, and Compliance Officer, as well as VP of Global Head of Strategy.

Before joining Roche, Dr. Eckelmann worked as a Pharmaceutical Industry Strategy Consultant for various leading pharmaceutical, biotech, and life sciences companies, providing research, project management, and sustainability expertise. Oliver started their career as a Summer Associate at Roland Berger Strategy Consultants.

Oliver Eckelmann, Ph.D. has an extensive and diverse education history. Oliver began their academic journey in 1998, attending EBS Universität für Wirtschaft und Recht. There, they pursued a degree in Business Administration, with a focus on Marketing and Entrepreneurship. Oliver successfully completed their studies and earned a Diplom Kauffmann in 2002.

Following this, Oliver furthered their education at IMD, where they pursued a Doctor of Philosophy (Ph.D.) in Business Administration, specializing in Strategic Pharma Management. Oliver dedicated three years to their doctoral studies, graduating in 2005.

Seeking additional knowledge and skills, Oliver enrolled at the University of Pittsburgh Katz Graduate School of Business in 2000. Oliver pursued an MBA, focusing on Business Administration with a specialization in Corporate Strategy & Finance. Oliver completed their studies in 2001.

In 2008, Oliver returned to IMD to undertake the Roche Executive Leadership Programme - Engage. This specialized program aimed to enhance their leadership abilities in a corporate setting.

In 2011, they attended Loroch Communication and Training in Life Science to gain a deeper understanding of Molecular Biology through the program "Molecular Biology for Non-Scientists."

Lastly, in 2013, Oliver Eckelmann enrolled in the Duke Corporate Education - Roche Executive Leadership Programme - Catalyst. This program, hosted by Duke University's Fuqua School of Business, aimed to further develop their executive leadership skills.

Oliver Eckelmann, Ph.D. has consistently pursued educational opportunities throughout their career, specializing in business administration, leadership development, and molecular biology.